March 11, 2020 12:30 UTC –Topline results from pivotal Phase 2b study of livoletide in patients with Prader-Willi syndrome (PWS) expected in early 2Q20– –Topline results from first cohort of Phase 2b study of nevanimibe in patients with classic congenital adrenal hyperplasia (CAH) expected in 2H20– –Successful financings strengthen financial position, extending cash runway into 2022– ANN ARBOR, Mich.--( BUSINESS WIRE )-- Millendo Therapeutics, Inc. (Nasdaq:
March 11, 2020
· 12 min read